Skip to main content

Evidence Account Cart (0)

Compounds/Muscle & Performance

Research pathway

Muscle & Performance

Catalogue index

Compounds in this category

Sort by

Published compounds 20Last publication 2026-10-04

EmberPeptides

New compound releases, research notes, and evidence updates—sent as they are published.

Frequently asked questions

Email address

I agree to receive research and catalogue updates by email.

Catalogue & research

All products
Single compounds
Research sets
FAQ
Newsletter sign-up
Research areas
Shipping
Account

Research

Overview
Evidence library
Articles
Glossary

Catalogue

Canadian catalogue
Research use only
Not for human use

© 2026 Ember Peptides

Terms of use Privacy policy

CanadaCAD

Research set
Wolverine
CA$530.00
Single compound
Ipamorelin
Selective GHS-R1a agonist — GH release · Preclinical
CA$55.00& up
Evidence tierAnimalRaun et al., European Journal of Endocrinology 1998 1 study
The pharmacology study characterized ipamorelin as a selective growth-hormone secretagogue. ↗Rat and swine pharmacologyRaun et al., European Journal of Endocrinology 1998Animal
Variant
Single compound
IGF-1 LR3
IGF-1 analogue — reduced IGFBP affinity · In vitro
CA$55.00& up
Evidence tierIn vitroPrice, Experimental Lung Research 2004 1 study
The cell-culture study reported proliferative stimulation in that conditioned-medium model. ↗Cultured postnatal rat lung fibroblastsPrice, Experimental Lung Research 2004In vitro
Variant
Single compound
Tesamorelin
GHRH analogue — approved indication exists · Phase 3
CA$170.00
Evidence tierPhase 3Falutz et al., NEJM 2007 2 studies
The trial reported a −15.2% CT visceral-adipose-tissue change compared with +5.0% for placebo. ↗412 HIV-positive adults with abdominal-fat accumulationFalutz et al., NEJM 2007Phase 3
Variant